Clinical Trial Detail

NCT ID NCT01894061
Title NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

glioblastoma multiforme

gliosarcoma

Therapies

Bevacizumab

Age Groups: adult

No variant requirements are available.